Oral melphalan pharmacokinetics — relation to dose in patients with multiple myeloma
The pharmacokinetics of melphalan have been studied after oral doses of 5,10 and 20 mg, and 10 mg i.v. Seven patients with multiple myeloma received the drug on 4 consecutive days and the concentration of melphalan was determined by liquid chromatography. Melphalan was rapidly absorbed after p.o. administration. Absorption lag-time was less than 1 h. The median time for attaining the peak concentration was 1.12 h (97% confidence interval: 0.68–1.55), 1.21 h (0.85–1.43) and 1.08 h (0.84–1.29) after doses of 5,10 and 20 mg. The bioavailability showed large interindividual variations, and was not significantly affected by the dose given. There was a significant decrease in bioavailability during the treatment course (P < 0.05). Absorption of melphalan obeys first-order kinetics in the dose interval studied. The results indicate that it might be of benefit to administrate oral melphalan for fewer days than the usually used 4 day regimen, in an attempt to achieve a higher bioavailability.
Key wordsMelphalan Pharmacokinetics Oral administration Chemotherapy Multiple myeloma
Unable to display preview. Download preview PDF.
- 2.Alberts D S, Chang S Y, Chen H S G, Evans T L, Moon T E: Oral melphalan kinetics.Clin Pharmac Ther 26, 737 (1979).Google Scholar
- 10.Reece P A, Kotasek D, Morris R G, Dale B M, Sage R E: The effect of food on oral melphalan absorption.Cancer Chemother Pharmac 16, 194 (1986).Google Scholar
- 11.Bosanquet A G, Gilby E D: Comparison of fed and fasting states on the absorption of melphalan in multiple myeloma.Cancer Chemother Pharmac 12, 183 (1984).Google Scholar
- 12.Ninane J, Baurain R, de Selys A, Trouet A, Cornu G: High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.Cancer Chemother Pharmac 15, 263 (1985).Google Scholar